Monoclonal antibodies 1G12 and 6A12 to the N-domain of human angiotensin-converting enzyme

Fine epitope mapping and antibody-based detection of ACE inhibitors in human blood

Irina V. Balyasnikova, Olga E. Skirgello, Petr V. Binevski, Andrei B. Nesterovitch, Ronald F. Albrecht, Olga A. Kost, Sergei M. Danilov*

*Corresponding author for this work

Research output: Contribution to journalArticle

23 Citations (Scopus)

Abstract

Angiotensin I-converting enzyme (ACE), a key enzyme in cardiovascular pathophysiology, consists of two homologous domains (N- and C-), each bearing a Zn-dependent active site. ACE inhibitors are among the most prescribed drugs in the treatment of hypertension and cardiac failure. Fine epitope mapping of two monoclonal antibodies (mAb), 1G12 and 6A12, against the N-domain of human ACE, was developed using the N-domain 3D-structure and 21 single and double N-domain mutants. The binding of both mAbs to their epitopes on the N-domain of ACE is significantly diminished by the presence of the C-domain in the two-domain somatic tissue ACE and further diminished by the presence of sialic acid residues on the surface of blood ACE. The binding of these mAbs to blood ACE, however, increased dramatically (5-10-fold) in the presence of ACE inhibitors or EDTA, whereas the effect of these compounds on the binding of the mAbs to somatic tissue ACE was less pronounced and even less for truncated N-domain. This implies that the binding of ACE inhibitors or removal of Zn2+ from ACE active centers causes conformational adjustments in the mutual arrangement of N- and C-domains in the two-domain ACE molecule. As a result, the regions of the epitopes for mAb 1G12 and 6A12 on the N-domain, shielded in somatic ACE by the C-domain globule and additionally shielded in blood ACE by sialic acid residues in the oligosaccharide chains localized on Asn289 and Asn416, become unmasked. Therefore, we demonstrated a possibility to employ these mAbs (1G12 or 6A12) for detection and quantification of the presence of ACE inhibitors in human blood. This method should find wide application in monitoring clinical trials with ACE inhibitors as well as in the development of the approach for personalized medicine by these effective drugs.

Original languageEnglish (US)
Pages (from-to)1580-1594
Number of pages15
JournalJournal of Proteome Research
Volume6
Issue number4
DOIs
StatePublished - Apr 1 2007

Fingerprint

Epitope Mapping
Peptidyl-Dipeptidase A
Angiotensin-Converting Enzyme Inhibitors
Epitopes
Blood
Antibodies
N-Acetylneuraminic Acid
6A12 monoclonal antibody
1G12 monoclonal antibody
Bearings (structural)
Tissue
Precision Medicine
Treatment Failure
Oligosaccharides
Edetic Acid
Pharmaceutical Preparations
Medicine
Catalytic Domain
Heart Failure

Keywords

  • ACE inhibitors
  • Angiotensin-converting enzyme
  • Blood
  • Conformational changes
  • Epitope mapping
  • Monoclonal antibody

ASJC Scopus subject areas

  • Chemistry(all)
  • Biochemistry

Cite this

Balyasnikova, Irina V. ; Skirgello, Olga E. ; Binevski, Petr V. ; Nesterovitch, Andrei B. ; Albrecht, Ronald F. ; Kost, Olga A. ; Danilov, Sergei M. / Monoclonal antibodies 1G12 and 6A12 to the N-domain of human angiotensin-converting enzyme : Fine epitope mapping and antibody-based detection of ACE inhibitors in human blood. In: Journal of Proteome Research. 2007 ; Vol. 6, No. 4. pp. 1580-1594.
@article{05c3b8ace318409a91ebfa9ba3b7dc84,
title = "Monoclonal antibodies 1G12 and 6A12 to the N-domain of human angiotensin-converting enzyme: Fine epitope mapping and antibody-based detection of ACE inhibitors in human blood",
abstract = "Angiotensin I-converting enzyme (ACE), a key enzyme in cardiovascular pathophysiology, consists of two homologous domains (N- and C-), each bearing a Zn-dependent active site. ACE inhibitors are among the most prescribed drugs in the treatment of hypertension and cardiac failure. Fine epitope mapping of two monoclonal antibodies (mAb), 1G12 and 6A12, against the N-domain of human ACE, was developed using the N-domain 3D-structure and 21 single and double N-domain mutants. The binding of both mAbs to their epitopes on the N-domain of ACE is significantly diminished by the presence of the C-domain in the two-domain somatic tissue ACE and further diminished by the presence of sialic acid residues on the surface of blood ACE. The binding of these mAbs to blood ACE, however, increased dramatically (5-10-fold) in the presence of ACE inhibitors or EDTA, whereas the effect of these compounds on the binding of the mAbs to somatic tissue ACE was less pronounced and even less for truncated N-domain. This implies that the binding of ACE inhibitors or removal of Zn2+ from ACE active centers causes conformational adjustments in the mutual arrangement of N- and C-domains in the two-domain ACE molecule. As a result, the regions of the epitopes for mAb 1G12 and 6A12 on the N-domain, shielded in somatic ACE by the C-domain globule and additionally shielded in blood ACE by sialic acid residues in the oligosaccharide chains localized on Asn289 and Asn416, become unmasked. Therefore, we demonstrated a possibility to employ these mAbs (1G12 or 6A12) for detection and quantification of the presence of ACE inhibitors in human blood. This method should find wide application in monitoring clinical trials with ACE inhibitors as well as in the development of the approach for personalized medicine by these effective drugs.",
keywords = "ACE inhibitors, Angiotensin-converting enzyme, Blood, Conformational changes, Epitope mapping, Monoclonal antibody",
author = "Balyasnikova, {Irina V.} and Skirgello, {Olga E.} and Binevski, {Petr V.} and Nesterovitch, {Andrei B.} and Albrecht, {Ronald F.} and Kost, {Olga A.} and Danilov, {Sergei M.}",
year = "2007",
month = "4",
day = "1",
doi = "10.1021/pr060658x",
language = "English (US)",
volume = "6",
pages = "1580--1594",
journal = "Journal of Proteome Research",
issn = "1535-3893",
publisher = "American Chemical Society",
number = "4",

}

Monoclonal antibodies 1G12 and 6A12 to the N-domain of human angiotensin-converting enzyme : Fine epitope mapping and antibody-based detection of ACE inhibitors in human blood. / Balyasnikova, Irina V.; Skirgello, Olga E.; Binevski, Petr V.; Nesterovitch, Andrei B.; Albrecht, Ronald F.; Kost, Olga A.; Danilov, Sergei M.

In: Journal of Proteome Research, Vol. 6, No. 4, 01.04.2007, p. 1580-1594.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Monoclonal antibodies 1G12 and 6A12 to the N-domain of human angiotensin-converting enzyme

T2 - Fine epitope mapping and antibody-based detection of ACE inhibitors in human blood

AU - Balyasnikova, Irina V.

AU - Skirgello, Olga E.

AU - Binevski, Petr V.

AU - Nesterovitch, Andrei B.

AU - Albrecht, Ronald F.

AU - Kost, Olga A.

AU - Danilov, Sergei M.

PY - 2007/4/1

Y1 - 2007/4/1

N2 - Angiotensin I-converting enzyme (ACE), a key enzyme in cardiovascular pathophysiology, consists of two homologous domains (N- and C-), each bearing a Zn-dependent active site. ACE inhibitors are among the most prescribed drugs in the treatment of hypertension and cardiac failure. Fine epitope mapping of two monoclonal antibodies (mAb), 1G12 and 6A12, against the N-domain of human ACE, was developed using the N-domain 3D-structure and 21 single and double N-domain mutants. The binding of both mAbs to their epitopes on the N-domain of ACE is significantly diminished by the presence of the C-domain in the two-domain somatic tissue ACE and further diminished by the presence of sialic acid residues on the surface of blood ACE. The binding of these mAbs to blood ACE, however, increased dramatically (5-10-fold) in the presence of ACE inhibitors or EDTA, whereas the effect of these compounds on the binding of the mAbs to somatic tissue ACE was less pronounced and even less for truncated N-domain. This implies that the binding of ACE inhibitors or removal of Zn2+ from ACE active centers causes conformational adjustments in the mutual arrangement of N- and C-domains in the two-domain ACE molecule. As a result, the regions of the epitopes for mAb 1G12 and 6A12 on the N-domain, shielded in somatic ACE by the C-domain globule and additionally shielded in blood ACE by sialic acid residues in the oligosaccharide chains localized on Asn289 and Asn416, become unmasked. Therefore, we demonstrated a possibility to employ these mAbs (1G12 or 6A12) for detection and quantification of the presence of ACE inhibitors in human blood. This method should find wide application in monitoring clinical trials with ACE inhibitors as well as in the development of the approach for personalized medicine by these effective drugs.

AB - Angiotensin I-converting enzyme (ACE), a key enzyme in cardiovascular pathophysiology, consists of two homologous domains (N- and C-), each bearing a Zn-dependent active site. ACE inhibitors are among the most prescribed drugs in the treatment of hypertension and cardiac failure. Fine epitope mapping of two monoclonal antibodies (mAb), 1G12 and 6A12, against the N-domain of human ACE, was developed using the N-domain 3D-structure and 21 single and double N-domain mutants. The binding of both mAbs to their epitopes on the N-domain of ACE is significantly diminished by the presence of the C-domain in the two-domain somatic tissue ACE and further diminished by the presence of sialic acid residues on the surface of blood ACE. The binding of these mAbs to blood ACE, however, increased dramatically (5-10-fold) in the presence of ACE inhibitors or EDTA, whereas the effect of these compounds on the binding of the mAbs to somatic tissue ACE was less pronounced and even less for truncated N-domain. This implies that the binding of ACE inhibitors or removal of Zn2+ from ACE active centers causes conformational adjustments in the mutual arrangement of N- and C-domains in the two-domain ACE molecule. As a result, the regions of the epitopes for mAb 1G12 and 6A12 on the N-domain, shielded in somatic ACE by the C-domain globule and additionally shielded in blood ACE by sialic acid residues in the oligosaccharide chains localized on Asn289 and Asn416, become unmasked. Therefore, we demonstrated a possibility to employ these mAbs (1G12 or 6A12) for detection and quantification of the presence of ACE inhibitors in human blood. This method should find wide application in monitoring clinical trials with ACE inhibitors as well as in the development of the approach for personalized medicine by these effective drugs.

KW - ACE inhibitors

KW - Angiotensin-converting enzyme

KW - Blood

KW - Conformational changes

KW - Epitope mapping

KW - Monoclonal antibody

UR - http://www.scopus.com/inward/record.url?scp=34248136986&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34248136986&partnerID=8YFLogxK

U2 - 10.1021/pr060658x

DO - 10.1021/pr060658x

M3 - Article

VL - 6

SP - 1580

EP - 1594

JO - Journal of Proteome Research

JF - Journal of Proteome Research

SN - 1535-3893

IS - 4

ER -